BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32157795)

  • 1. Crystals in Minutes: Instant On-Site Microcrystallisation of Various Flavours of the CYP102A1 (P450BM3) Haem Domain.
    Stanfield JK; Omura K; Matsumoto A; Kasai C; Sugimoto H; Shiro Y; Watanabe Y; Shoji O
    Angew Chem Int Ed Engl; 2020 May; 59(19):7611-7618. PubMed ID: 32157795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for the properties of two single-site proline mutants of CYP102A1 (P450BM3).
    Whitehouse CJ; Yang W; Yorke JA; Rowlatt BC; Strong AJ; Blanford CF; Bell SG; Bartlam M; Wong LL; Rao Z
    Chembiochem; 2010 Dec; 11(18):2549-56. PubMed ID: 21110374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding the applicability of cytochrome P450s and other haemoproteins.
    Ariyasu S; Stanfield JK; Aiba Y; Shoji O
    Curr Opin Chem Biol; 2020 Dec; 59():155-163. PubMed ID: 32781431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel haem co-ordination variants of flavocytochrome P450BM3.
    Girvan HM; Toogood HS; Littleford RE; Seward HE; Smith WE; Ekanem IS; Leys D; Cheesman MR; Munro AW
    Biochem J; 2009 Jan; 417(1):65-76. PubMed ID: 18721129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hoodwinking Cytochrome P450BM3 into Hydroxylating Non-Native Substrates by Exploiting Its Substrate Misrecognition.
    Shoji O; Aiba Y; Watanabe Y
    Acc Chem Res; 2019 Apr; 52(4):925-934. PubMed ID: 30888147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Mutation and Substrate Binding on the Stability of Cytochrome P450BM3 Variants.
    Geronimo I; Denning CA; Rogers WE; Othman T; Huxford T; Heidary DK; Glazer EC; Payne CM
    Biochemistry; 2016 Jun; 55(25):3594-606. PubMed ID: 27267136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P450
    Beyer N; Kulig JK; Bartsch A; Hayes MA; Janssen DB; Fraaije MW
    Appl Microbiol Biotechnol; 2017 Mar; 101(6):2319-2331. PubMed ID: 27900443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of full-length P450BM3 with an artificial metal complex by utilising the transpeptidase Sortase A.
    Omura K; Aiba Y; Onoda H; Stanfield JK; Ariyasu S; Sugimoto H; Shiro Y; Shoji O; Watanabe Y
    Chem Commun (Camb); 2018 Jul; 54(57):7892-7895. PubMed ID: 29845154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The full-length cytochrome P450 enzyme CYP102A1 dimerizes at its reductase domains and has flexible heme domains for efficient catalysis.
    Zhang H; Yokom AL; Cheng S; Su M; Hollenberg PF; Southworth DR; Osawa Y
    J Biol Chem; 2018 May; 293(20):7727-7736. PubMed ID: 29618513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryo-EM reveals the architecture of the dimeric cytochrome P450 CYP102A1 enzyme and conformational changes required for redox partner recognition.
    Su M; Chakraborty S; Osawa Y; Zhang H
    J Biol Chem; 2020 Feb; 295(6):1637-1645. PubMed ID: 31901079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options.
    Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL
    Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Determinants of Substrate Affinity and Enzyme Activity of a Cytochrome P450
    Geronimo I; Denning CA; Heidary DK; Glazer EC; Payne CM
    Biophys J; 2018 Oct; 115(7):1251-1263. PubMed ID: 30224054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the applicability of the CYP102A1-decoy-molecule system to other members of the CYP102A subfamily.
    Stanfield JK; Onoda H; Ariyasu S; Kasai C; Burfoot EM; Sugimoto H; Shoji O
    J Inorg Biochem; 2023 Aug; 245():112235. PubMed ID: 37167731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional interactions in cytochrome P450BM3: flavin semiquinone intermediates, role of NADP(H), and mechanism of electron transfer by the flavoprotein domain.
    Murataliev MB; Klein M; Fulco A; Feyereisen R
    Biochemistry; 1997 Jul; 36(27):8401-12. PubMed ID: 9204888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallographic insights into a cobalt (III) sepulchrate based alternative cofactor system of P450 BM3 monooxygenase.
    Panneerselvam S; Shehzad A; Mueller-Dieckmann J; Wilmanns M; Bocola M; Davari MD; Schwaneberg U
    Biochim Biophys Acta Proteins Proteom; 2018 Jan; 1866(1):134-140. PubMed ID: 28739446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resonance Raman studies of cytochrome P450BM3 and its complexes with exogenous ligands.
    Deng TJ; Proniewicz LM; Kincaid JR; Yeom H; Macdonald ID; Sligar SG
    Biochemistry; 1999 Oct; 38(41):13699-706. PubMed ID: 10521277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial alanine substitution enables rapid optimization of cytochrome P450BM3 for selective hydroxylation of large substrates.
    Lewis JC; Mantovani SM; Fu Y; Snow CD; Komor RS; Wong CH; Arnold FH
    Chembiochem; 2010 Dec; 11(18):2502-5. PubMed ID: 21108271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Evolved Orthogonal Enzyme/Cofactor Pair.
    Reynolds EW; McHenry MW; Cannac F; Gober JG; Snow CD; Brustad EM
    J Am Chem Soc; 2016 Sep; 138(38):12451-8. PubMed ID: 27575374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure, electronic properties and catalytic behaviour of an activity-enhancing CYP102A1 (P450(BM3)) variant.
    Whitehouse CJ; Yang W; Yorke JA; Tufton HG; Ogilvie LC; Bell SG; Zhou W; Bartlam M; Rao Z; Wong LL
    Dalton Trans; 2011 Oct; 40(40):10383-96. PubMed ID: 21603690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.